TABLE 2.
Distribution of HRQL scores before and after DAA treatment among PWID who participated in the quantitative study (n = 89, ANRS CO13 HEPAVIH cohort)
| HRQL dimensionsa | Treatment initiation | End of treatment | P‐valueb |
|---|---|---|---|
| Mean (SD) Median [IQR] | |||
| Physical functioning (n = 80) | 62.5 (34.9) 75 [50–100] |
64.1 (33.9) 75 [50–100] |
.48 |
| Limitations due to physical status (role‐physical) (n = 70) |
61.6 (28.7) 62.5 [50–87.5] |
67.3 (29.4) 75 [50–100] |
.047 |
| Bodily pain (n = 84) | 66.1 (28.9) 75 [50–100] | 72.9 (29.9) 75 [50–100] | .06 |
| General health (n = 82) |
53.4 (20.3) 60 [60–60] |
57.3 (19.6) 60 [60–60] |
.03 |
| Vitality (n = 76) | 39.1 (23.2) 50 [25–75] | 41.4 (29.3) 50 [25–75] | .53 |
| Social functioning (n = 82) |
57.6 (28.8) 50 [50–75] |
66.2 (26.2) 75 [50–100] |
.005 |
| Limitations dues to psychological status (role‐emotional) (n = 75) | 63.2 (27.6) 62.5 [50–87.5] |
68.5 (27.4) 75 [50–100] |
.14 |
| Mental health (n = 79) | 57.6 (21.3) 50 [37.5–75] |
60.0 (20.7) 62.5 [50–75] |
.13 |
Abbreviations: DAA, direct-acting antivirals; HRQL, health-related quality of life; IQR, interquartile range; PWID = people who inject drugs; SD, standard deviation.
a
Scores associated with the 8 dimensions of the MOS SF-12 v2 scale.
b
Wilcoxon signed-rank test for the before-after comparisons of scores. HRQL dimensions with P < .05 are in written in bold.